Blood cancers dominate CAR-T pipeline

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT).

The CAR-T landscape is dominated by blood cancers, with industry leaders like Bristol Myers Squibb (NYSE: BMY) at the forefront of this revolution, driving advancements that have the potential to redefine treatment paradigms for blood cancers, such as B-cell acute lymphocytic leukemia, says pharma analytics company GlobalData, which noted that blood cancers account for over half of all CAR-Ts in the active pipeline and make up nine out of the top 10 CAR-T indications.

CAR-T therapeutics are a leading type of T-cell immunotherapy, accounting for over half of the approvals in the oncology CGT landscape. This therapeutic modality involves genetically engineering autologous or allogeneic T-cells to express a chimeric antigen receptor so they actively recognize and destroy cancerous cells.